NECLIFE — Nectar Lifesciences Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapContrarian

Annual income statement for Nectar Lifesciences, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IAS	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	23,664	15,444	16,688	15,237	16,841
Cost of Revenue
Gross Profit	3,688	2,586	2,993	2,063	3,159
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	22,074	15,197	15,673	15,289	15,917
Operating Profit	1,590	247	1,016	-52	924
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	375	-848	341	-424	183
Provision for Income Taxes
Net Income After Taxes	318	-733	250	-242	50
Net Income Before Extraordinary Items
Net Income	318	-733	250	-242	50
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	318	-733	250	-242	50
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1.41	-2.53	0.809	-2.25	0.223
Dividends per Share